Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives $35.71 Average Target Price from Analysts

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) has been assigned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $35.71.

A number of analysts have issued reports on DAWN shares. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research note on Thursday, August 1st. Wedbush reaffirmed an “outperform” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. Bank of America raised shares of Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and raised their price target for the company from $11.00 to $24.00 in a research report on Thursday, August 1st. Needham & Company LLC reaffirmed a “buy” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Tuesday, July 30th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research note on Monday, July 8th.

Day One Biopharmaceuticals Stock Performance

Shares of DAWN stock opened at $13.79 on Friday. Day One Biopharmaceuticals has a one year low of $9.67 and a one year high of $18.07. The firm’s 50 day moving average price is $14.28 and its 200-day moving average price is $14.56. The firm has a market cap of $1.21 billion, a P/E ratio of -5.49 and a beta of -1.51.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings results on Tuesday, July 30th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.70. The firm had revenue of $8.19 million for the quarter, compared to analysts’ expectations of $0.90 million. As a group, research analysts predict that Day One Biopharmaceuticals will post -1.68 EPS for the current fiscal year.

Insider Activity

In related news, Director Saira Ramasastry sold 10,000 shares of Day One Biopharmaceuticals stock in a transaction on Friday, June 21st. The shares were sold at an average price of $13.19, for a total transaction of $131,900.00. Following the sale, the director now directly owns 40,485 shares in the company, valued at approximately $533,997.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, General Counsel Adam Dubow sold 3,202 shares of Day One Biopharmaceuticals stock in a transaction on Friday, August 16th. The shares were sold at an average price of $14.00, for a total value of $44,828.00. Following the transaction, the general counsel now directly owns 26,928 shares of the company’s stock, valued at approximately $376,992. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Saira Ramasastry sold 10,000 shares of the company’s stock in a transaction on Friday, June 21st. The shares were sold at an average price of $13.19, for a total transaction of $131,900.00. Following the completion of the sale, the director now owns 40,485 shares of the company’s stock, valued at approximately $533,997.15. The disclosure for this sale can be found here. In the last quarter, insiders sold 78,748 shares of company stock worth $1,141,172. Corporate insiders own 8.40% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Quintet Private Bank Europe S.A. raised its holdings in shares of Day One Biopharmaceuticals by 43.2% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock valued at $48,000 after buying an additional 1,000 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its stake in Day One Biopharmaceuticals by 2.5% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 59,289 shares of the company’s stock valued at $979,000 after acquiring an additional 1,445 shares during the last quarter. ProShare Advisors LLC lifted its position in Day One Biopharmaceuticals by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 17,379 shares of the company’s stock worth $287,000 after acquiring an additional 1,447 shares during the period. Quest Partners LLC purchased a new position in shares of Day One Biopharmaceuticals in the 4th quarter valued at approximately $29,000. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Day One Biopharmaceuticals by 1.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 452,934 shares of the company’s stock valued at $6,613,000 after purchasing an additional 5,796 shares during the last quarter. 87.95% of the stock is owned by hedge funds and other institutional investors.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.